In a meta-analysis by Zeng et al. that included 2569 cancer patients (reflecting 13 common solid malignancies), increased Trop-2 expression was particularly associated with poor overall survival (OS) and disease-free survival (DFS) outcomes in patients with gastrointestinal and gynecological malignancies [18]. This evidence concerns the gene TACSTD2 and cancer.